jQuery is a feature-rich JavaScript library. jQuery makes the things like animation,events handling, and Ajax much simpler with an easy-to-use API that works across a multitude of browsers. Here we ...

The estimated 2022 incidence of overall ATTR amyloidosis, transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), and transthyretin amyloid polyneuropathy (ATTR-PN) were 16.6, 12.7, and 3.5 cases per ...

The low positive predictive value indicates that a positive diagnosis using planar imaging would result in an incorrect diagnosis of ATTR-CM 42% of the time. Calculating visual scores using ...

Angela Ryan Lee, MD, FACC, is a board-certified cardiology and internal medicine physician. She also holds board certifications from the American Society of Nuclear Cardiology and the National Board ...

The burgeoning field of transthyretin amyloid cardiomyopathy (ATTR-CM), which spurred excitement over a potential $20 billion market, may have just revealed the first indication of a slowdown. For the ...

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a condition that makes the heart stiff and less flexible, making it harder for the heart to pump. ATTR-CM doesn't always cause symptoms. When it does, ...

Fatigue is one of the most frustrating symptoms of transthyretin cardiac amyloidosis (ATTR-CM). It can reduce your overall quality of life, limiting your ability to complete daily tasks and ...

ATTR-CM can be a life-changing diagnosis, and if you’re an older adult, it can have an especially large impact on your quality of life. Transthyretin amyloidosis cardiomyopathy (ATTR-CM) is a rare but ...

The last time I spoke about Intellia Therapeutics (NTLA), it was with a Seeking Alpha article entitled "Nex-Z Advancement Remains On Track With Expanded ATTRv-PN Indication" With respect to this ...

Sleep problems are extremely common when youre living with transthyretin amyloid cardiomyopathy (ATTR-CM). This heart condition involves misshapen transthyretin protein building up in your heart ...

With several disease-modifying therapies available for transthyretin amyloid cardiomyopathy (ATTR-CM) -- and more waiting in the wings -- choosing one has become a new challenge, with softer endpoints ...